 |
 |
Regulates, compensates, reinforces the bodies defense's
Thymoenzym 2G
Mechanism of Action:
The immune system is made up by cellular and humoral elements whose
main function is the defence of the body’s well-being, with the ability to recognise
its own and foreign substances.
If a microorganism succeeds in getting through the body’s defence barriers, the
first reaction is inflammation. During the first 12 to 24 hours, the cells that act are the polymorphonuclear neutrophils, with great phagocytic power, and, to a lesser degree, the eosinophils. After this time, the mononuclear macrophages appear, also with phagocytic power, directing the antigens and neutrophils that phagocytosed antigens. In addition to this, the fibrinogen becomes fibrin, formng small local clots that try to impede the dissemination of the antigen.
The changes in the regulation and functioning of the immune system lead to diseases that will present different signs, according to the type of dysfunction.
The diminished oversight of the immune system is connected to a greater frequency and seriousness of infections, as well as to the development of tumours. Other times, the body lacks the immune resources in a sufficient quantity or variety to counteract the penetration of outside agents such as viruses, bacteria, fungi, or the generation of tumour cells. In these cases, what we have are cases of immune deficiency and we need components that stimulate the immune response. Thymoenzym 2G’s components activate all immune defence mechanisms, consolidating the action of T-cells, which are essential for proper functioning of the immune system. In addition, it elevates the number of cells that manifest markers and surface function in T-cells. Now, with the incorporation in its formula of embryonic cell extracts, it will have a greater influence on pre-T cells. Therefore, it has potential therapeutic applications in different T-cell deficiency conditions. . A recombinant peptide derived from this formula, such as thymosin alpha-1, induces increases in the production of interleucine 2 (IL-2) and the expression of IL-2 receptors in the LT. This peptide is also being used for treatments of cancer and chronic active hepatitis.
 |
||
More Information |
||
| » Thymoenzym 2G » Clinical Information and Pharmacology » Mechanisms of Action » Pharmacokinetics |
» Indications » Oncology » Analysis » Clinical Studies |
» Bibliography » Exclusively For Doctors |